PHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Phreesia Inc (PHR) is not a strong buy for a beginner investor with a long-term strategy at this time. The company's recent financial performance shows declining profitability, insider selling has increased significantly, and Congress trading data indicates caution. Additionally, analysts have lowered price targets and expressed concerns about growth visibility. While the stock has potential for short-term gains, the lack of strong positive catalysts and the current pre-market price decline make it unsuitable for a long-term investment at this stage.
The MACD is positive but contracting, RSI is neutral at 39.035, and moving averages are converging. The stock is trading near its pivot point of 8.871, with key resistance at 9.66 and support at 8.082. Overall, the technical indicators suggest a lack of clear upward momentum.
Analysts believe the healthcare system's utilization supports software spending, and the company is rolling out efficiency initiatives to address disruptions.
Net income dropped by 120.27% YoY, EPS fell by 118.18% YoY, and gross margin declined by 4.10%. Insider selling increased by 190.73% last month, and Congress members have sold shares recently. Analysts have downgraded the stock and lowered price targets due to reduced growth visibility and disappointing fiscal 2027 revenue guidance.
In Q4 2026, revenue increased by 15.85% YoY to $127.07M, but net income dropped by 120.27% YoY to $1.29M. EPS declined by 118.18% YoY to $0.02, and gross margin fell to 60.59%, down 4.10% YoY. These metrics indicate declining profitability despite revenue growth.
Analysts have lowered price targets significantly, with the most recent targets ranging from $10 to $22. Multiple firms downgraded the stock, citing disappointing fiscal 2027 revenue guidance, reduced growth visibility, and macroeconomic pressures. While some analysts maintain long-term conviction, the near-term outlook remains uncertain.
